Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins
- Author
- HALLER, Aurelia A1 ; LAUER, Georg M2 ; DUKE, Richard C1 3 ; KING, Thomas H1 ; KEMMLER, Charles1 ; FIOLKOSKI, Valerie1 ; YINGNIAN LU1 ; BELLGRAU, Don1 3 ; RODELL, Timothy C1 ; APELIAN, David1 ; FRANZUSOFF, Alex1
[1] GlobeImmune, Inc., 1450 Infinite Drive, Louisville, CO 80027, United States
[2] Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, United States
[3] Departments of Immunology and Medicine, University of Colorado at Denver and Health Sciences Center, 4200 East Ninth Avenue, Denver. CO 80262, United States - Source
Vaccine. 2007, Vol 25, Num 8, pp 1452-1463, 12 p ; ref : 30 ref
- CODEN
- VACCDE
- ISSN
- 0264-410X
- Scientific domain
- Biotechnology; Immunology, immunopathology, allergology; Microbiology, infectious diseases; Virology
- Publisher
- Elsevier, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- HCV Hepatitis C Immunotherapy S. cerevisiae Vaccine Yeast
- Keyword (fr)
- Adressage moléculaire Hépatite virale C Immunité cellulaire Immunothérapie Levure Vaccin Virus hépatite C Appareil digestif pathologie Flaviviridae Foie pathologie Hepacivirus Infection Virose Virus
- Keyword (en)
- Molecular targeting Viral hepatitis C Cellular immunity Immunotherapy Yeast Vaccine Hepatitis C virus Digestive diseases Flaviviridae Hepatic disease Hepacivirus Infection Viral disease Virus
- Keyword (es)
- Direccionamiento molecular Hepatitis virica C Inmunidad celular Inmunoterapia Levadura Vacuna Hepatitis C virus Aparato digestivo patología Flaviviridae Hígado patología Hepacivirus Infección Virosis Virus
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A05 Microbiology / 002A05C Virology / 002A05C10 Miscellaneous
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A05 Microbiology / 002A05F Applied microbiology / 002A05F04 Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02G Viral hepatitis
- Discipline
- Infectious pathology Microbiology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18473826
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.vaccine.2006.10.035 
https://dx.doi.org/10.1016/j.vaccine.2006.10.035
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2006.10.035\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1463\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HALLER\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Aurelia A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"LAUER, Georg M\";i:1;s:15:\"DUKE, Richard C\";i:2;s:14:\"KING, Thomas H\";i:3;s:16:\"KEMMLER, Charles\";i:4;s:18:\"FIOLKOSKI, Valerie\";i:5;s:11:\"YINGNIAN LU\";i:6;s:13:\"BELLGRAU, Don\";i:7;s:17:\"RODELL, Timothy C\";i:8;s:14:\"APELIAN, David\";i:9;s:16:\"FRANZUSOFF, Alex\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2006.10.035\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1463\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HALLER\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Aurelia A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"LAUER, Georg M\";i:1;s:15:\"DUKE, Richard C\";i:2;s:14:\"KING, Thomas H\";i:3;s:16:\"KEMMLER, Charles\";i:4;s:18:\"FIOLKOSKI, Valerie\";i:5;s:11:\"YINGNIAN LU\";i:6;s:13:\"BELLGRAU, Don\";i:7;s:17:\"RODELL, Timothy C\";i:8;s:14:\"APELIAN, David\";i:9;s:16:\"FRANZUSOFF, Alex\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2006.10.035\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2006.10.035\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1463\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HALLER\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Aurelia A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"LAUER, Georg M\";i:1;s:15:\"DUKE, Richard C\";i:2;s:14:\"KING, Thomas H\";i:3;s:16:\"KEMMLER, Charles\";i:4;s:18:\"FIOLKOSKI, Valerie\";i:5;s:11:\"YINGNIAN LU\";i:6;s:13:\"BELLGRAU, Don\";i:7;s:17:\"RODELL, Timothy C\";i:8;s:14:\"APELIAN, David\";i:9;s:16:\"FRANZUSOFF, Alex\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2006.10.035\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1463\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HALLER\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Aurelia A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"LAUER, Georg M\";i:1;s:15:\"DUKE, Richard C\";i:2;s:14:\"KING, Thomas H\";i:3;s:16:\"KEMMLER, Charles\";i:4;s:18:\"FIOLKOSKI, Valerie\";i:5;s:11:\"YINGNIAN LU\";i:6;s:13:\"BELLGRAU, Don\";i:7;s:17:\"RODELL, Timothy C\";i:8;s:14:\"APELIAN, David\";i:9;s:16:\"FRANZUSOFF, Alex\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2006.10.035\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1463\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HALLER\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Aurelia A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"LAUER, Georg M\";i:1;s:15:\"DUKE, Richard C\";i:2;s:14:\"KING, Thomas H\";i:3;s:16:\"KEMMLER, Charles\";i:4;s:18:\"FIOLKOSKI, Valerie\";i:5;s:11:\"YINGNIAN LU\";i:6;s:13:\"BELLGRAU, Don\";i:7;s:17:\"RODELL, Timothy C\";i:8;s:14:\"APELIAN, David\";i:9;s:16:\"FRANZUSOFF, Alex\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
